{
    "clinical_study": {
        "@rank": "53907", 
        "arm_group": [
            {
                "arm_group_label": "Gemcitabine + Capecitabine", 
                "arm_group_type": "Active Comparator", 
                "description": "Gemcitabine + Capecitabine"
            }, 
            {
                "arm_group_label": "Gemcitabine alone", 
                "arm_group_type": "Active Comparator", 
                "description": "Gemcitabine alone"
            }
        ], 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. It is not yet known if gemcitabine is more effective with or\n      without capecitabine in treating pancreatic cancer.\n\n      PURPOSE: Randomized phase III trial to determine the effectiveness of gemcitabine with or\n      without capecitabine in treating patients who have advanced pancreatic cancer."
        }, 
        "brief_title": "Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer", 
        "completion_date": {
            "#text": "April 2008", 
            "@type": "Actual"
        }, 
        "condition": "Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Compare the overall survival of patients with advanced pancreatic cancer treated with\n           gemcitabine with or without capecitabine.\n\n        -  Compare the clinical benefit response, objective tumor response, duration of response,\n           and time to progression in patients treated with these regimens.\n\n        -  Compare the toxicity of these regimens in these patients.\n\n        -  Compare the quality of life of patients treated with these regimens.\n\n      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to\n      metastases (yes vs no), pain (yes vs no), Karnofsky performance status (60-80% vs 90-100%),\n      and participating center. Patients are randomized to 1 of 2 treatment arms.\n\n        -  Arm I: Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and oral\n           capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks in the absence\n           of disease progression or unacceptable toxicity.\n\n        -  Arm II: Patients initially receive gemcitabine IV over 30 minutes weekly for 7 weeks.\n           After 1 week of rest, patients receive gemcitabine IV over 30 minutes weekly for 3\n           weeks. Treatment then repeats every 4 weeks in the absence of disease progression or\n           unacceptable toxicity.\n\n      Quality of life is assessed at baseline, weekly for weeks 2-7, and then before each\n      gemcitabine administration.\n\n      Patients are followed every 9 weeks.\n\n      PROJECTED ACCRUAL: A total of 300 patients (150 per treatment arm) will be accrued for this\n      study within 3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically or cytologically confirmed primary inoperable or metastatic pancreatic\n             adenocarcinoma\n\n          -  No CNS metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Over 18\n\n        Performance status:\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  WBC at least 3,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n          -  Hemoglobin at least 10.0 g/dL\n\n        Hepatic:\n\n          -  Bilirubin no greater than 5 times normal\n\n          -  AST/ALT no greater than 5 times normal\n\n          -  Alkaline phosphatase no greater than 5 times normal\n\n        Renal:\n\n          -  Creatinine clearance at least 30 mL/min\n\n        Gastrointestinal:\n\n          -  No grade 2 or greater nausea or grade 1 or greater vomiting\n\n          -  No medical condition that would interfere with taking oral medications or with\n             gastrointestinal absorption (e.g., small bowel obstruction)\n\n        Other:\n\n          -  No prior unanticipated severe reaction to fluoropyrimidine therapy\n\n          -  No known hypersensitivity to fluorouracil\n\n          -  No known dihydropyrimidine dehydrogenase deficiency\n\n          -  No active infection\n\n          -  No other serious concurrent systemic disorders that would preclude study\n             participation\n\n          -  No other malignancy within the past 5 years except adequately treated carcinoma in\n             situ of the cervix or basal cell skin cancer\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  No prior capecitabine\n\n          -  No prior chemotherapy for advanced pancreatic cancer\n\n          -  At least 1 year since prior radiochemotherapy for pancreatic cancer\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  See Chemotherapy\n\n          -  At least 1 year since prior adjuvant radiotherapy for pancreatic cancer\n\n          -  No concurrent radiotherapy\n\n        Surgery:\n\n          -  Prior Whipple procedure or duodenal bypass allowed\n\n        Other:\n\n          -  At least 1 month since prior investigational agents\n\n          -  No concurrent sorivudine or its chemically related analogues (e.g., brivudine)\n\n          -  No other concurrent anticancer or investigational drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "319", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 14, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00030732", 
            "org_study_id": "SAKK 44/00", 
            "secondary_id": [
                "SWS-SAKK-44/00", 
                "CECOG/PAN-1.3.001", 
                "EU-20142"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Gemcitabine + Capecitabine", 
                "description": "Gemcitabine + Capecitabine", 
                "intervention_name": "Gemcitabine + Capecitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Gemcitabine alone", 
                "description": "Gemcitabine alone", 
                "intervention_name": "Gemcitabine alone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Capecitabine", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "stage III pancreatic cancer", 
            "recurrent pancreatic cancer", 
            "adenocarcinoma of the pancreas", 
            "stage IV pancreatic cancer"
        ], 
        "lastchanged_date": "May 14, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria", 
                        "zip": "A-1090"
                    }, 
                    "name": "Allgemeines Krankenhaus der Stadt Wien"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tel-Aviv", 
                        "country": "Israel", 
                        "zip": "64239"
                    }, 
                    "name": "Tel-Aviv Sourasky Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milan", 
                        "country": "Italy", 
                        "zip": "20133"
                    }, 
                    "name": "Istituto Nazionale per lo Studio e la Cura dei Tumori"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Naples", 
                        "country": "Italy", 
                        "zip": "80131"
                    }, 
                    "name": "Istituto Nazionale per lo Studio e la Cura dei Tumori"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aarau", 
                        "country": "Switzerland", 
                        "zip": "5001"
                    }, 
                    "name": "Kantonspital Aarau"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Basel", 
                        "country": "Switzerland", 
                        "zip": "CH-4016"
                    }, 
                    "name": "Saint Claraspital AG"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Basel", 
                        "country": "Switzerland", 
                        "zip": "CH-4031"
                    }, 
                    "name": "Universitatsspital-Basel"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bern", 
                        "country": "Switzerland", 
                        "zip": "CH-3010"
                    }, 
                    "name": "Inselspital, Bern"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Biel", 
                        "country": "Switzerland", 
                        "zip": "CH-2501"
                    }, 
                    "name": "Spitalzentrum Biel"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chur", 
                        "country": "Switzerland", 
                        "zip": "CH-7000"
                    }, 
                    "name": "Ratisches Kantons und Regionalspital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Geneva", 
                        "country": "Switzerland", 
                        "zip": "CH-1211"
                    }, 
                    "name": "Hopital Cantonal Universitaire de Geneve"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lausanne", 
                        "country": "Switzerland", 
                        "zip": "CH-1011"
                    }, 
                    "name": "Centre Hospitalier Universitaire Vaudois"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sion", 
                        "country": "Switzerland", 
                        "zip": "CH1951"
                    }, 
                    "name": "Institut Central des Hopitaux Valaisans"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Gallen", 
                        "country": "Switzerland", 
                        "zip": "CH-9007"
                    }, 
                    "name": "Kantonsspital - St. Gallen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Thun", 
                        "country": "Switzerland", 
                        "zip": "3600"
                    }, 
                    "name": "Regionalspital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zurich", 
                        "country": "Switzerland", 
                        "zip": "8063"
                    }, 
                    "name": "City Hospital Triemli"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zurich", 
                        "country": "Switzerland", 
                        "zip": "CH-8091"
                    }, 
                    "name": "UniversitaetsSpital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zurich", 
                        "country": "Switzerland", 
                        "zip": "CH-8091"
                    }, 
                    "name": "Oncology Institute of Southern Switzerland"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Israel", 
                "Italy", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Gemcitabine Plus Capecitabine Versus Gemcitabine Alone In Advanced Pancreatic Cancer. A Randomized Phase III Trial", 
        "overall_official": [
            {
                "affiliation": "Universitaetsspital-Basel", 
                "last_name": "Richard Herrmann, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Allgemeines Krankenhaus - Universitatskliniken", 
                "last_name": "Werner Scheithauer, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To compare survival, efficacy, quality of life and toxicity between the combination therapy (Capecitabine and Gemcitabine) and the monotherapy (Gemcitabine alone) in advanced pancreatic cancer.", 
            "measure": "Gemcitabine + Capecitabine vs. Gemcitabine alone", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00030732"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": [
            {
                "PMID": "20877359", 
                "citation": "Bernhard J, Dietrich D, Glimelius B, Hess V, Bodoky G, Scheithauer W, Herrmann R. Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy. Br J Cancer. 2010 Sep 28; [Epub ahead of print]"
            }, 
            {
                "PMID": "18669454", 
                "citation": "Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Sch\u00fcller J, Saletti P, Bauer J, Figer A, Pestalozzi BC, K\u00f6hne CH, Mingrone W, Stemmer SM, T\u00e0mas K, Kornek GV, Koeberle D, Herrmann R; Central European Cooperative Oncology Group. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol. 2008 Aug 1;26(22):3695-701."
            }, 
            {
                "PMID": "18249033", 
                "citation": "Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, Bajetta E, Saletti P, Figer A, Scheithauer W, Herrmann R. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008 Feb;9(2):132-8."
            }, 
            {
                "PMID": "17538165", 
                "citation": "Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Kohne CH, Mingrone W, Stemmer SM, Tamas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W; Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007 Jun 1;25(16):2212-7."
            }, 
            {
                "citation": "Herrmann R, Bodoky G, Ruhstaller T, et al.: Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). [Abstract] J Clin Oncol 23 (Suppl 16): A-LBA4010, 310s, 2005."
            }
        ], 
        "source": "Swiss Group for Clinical Cancer Research", 
        "sponsors": {
            "collaborator": {
                "agency": "Central European Cooperative Oncology Group", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Swiss Group for Clinical Cancer Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2012"
    }, 
    "geocoordinates": {
        "Allgemeines Krankenhaus der Stadt Wien": "48.208 16.374", 
        "Centre Hospitalier Universitaire Vaudois": "46.52 6.634", 
        "City Hospital Triemli": "47.369 8.539", 
        "Hopital Cantonal Universitaire de Geneve": "46.198 6.142", 
        "Inselspital, Bern": "46.948 7.445", 
        "Institut Central des Hopitaux Valaisans": "46.229 7.362", 
        "Istituto Nazionale per lo Studio e la Cura dei Tumori": "40.84 14.253", 
        "Kantonspital Aarau": "47.391 8.046", 
        "Kantonsspital - St. Gallen": "47.424 9.371", 
        "Oncology Institute of Southern Switzerland": "47.369 8.539", 
        "Ratisches Kantons und Regionalspital": "46.857 9.527", 
        "Regionalspital": "46.748 7.626", 
        "Saint Claraspital AG": "47.557 7.593", 
        "Spitalzentrum Biel": "47.14 7.244", 
        "Tel-Aviv Sourasky Medical Center": "32.066 34.778", 
        "UniversitaetsSpital": "47.369 8.539", 
        "Universitatsspital-Basel": "47.557 7.593"
    }
}